CSPCPHARMA：ANNUALRESULTSFORTHEYEARENDED31DECEMBER2025.pdf

1、 1 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in rel

2、iance upon the whole or any part of the contents of this announcement.CSPC PHARMACEUTICAL GROUP LIMITED(Incorporated in Hong Kong with limited liability)(Stock Code:1093)石 藥 集 團 有 限 公 司ANNUAL RESULTSFOR THE YEAR ENDED 31 DECEMBER 2025The Board of Directors(the“Board”)of CSPC Pharmaceutical Group Lim

3、ited(the“Company”)is pleased to announce the audited consolidated results of the Company and its subsidiaries(together,the“Group”)for the year ended 31 December 2025.FINANCIAL HIGHLIGHTS(in RMB000,unless otherwise stated)20252024ChangeRevenue by business units:Finished drugs20,583,72923,736,157-13.3

4、%Bulk products3,656,9723,583,163+2.1%Functional food and others1,765,2791,689,934+4.5%Total revenue26,005,98029,009,254-10.4%Profit attributable to shareholders of the CompanyReported3,882,1084,328,035-10.3%Underlying(Note)3,534,3264,682,909-24.5%Earnings per share(RMB cents)Based on reported profit

5、 attributable to shareholders of the Company Basic33.9836.87-7.8%Diluted33.9836.87-7.8%Final dividend per share(HK cents)15.0010.00+50.0%Full-year dividend per share(HK cents)29.0026.00+11.5%Note:Underlying profit attributable to shareholders of the Company,a non-HKFRS Accounting Standards measure,r

6、epresents profit attributable to shareholders of the Company before taking into account fair value changes on financial assets measured at fair value through profit or loss(“FVTPL”),and employee share-based compensation expense.A reconciliation between reported and underlying profit is provided on p